Evidence mapPaperPMID 33728540Full record

ArticleInflammopharmacology2021

Anti-inflammatory potential of Empagliflozin.

Markus Pirklbauer

Abstract read
In one paragraph

Article in Inflammopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Empagliflozin Mitigates PTZ-Induced Seizures in Rats: Modulating Npas4 and CREB-BDNF Signaling Pathway.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Markus PirklbauerDepartment of Internal Medicine IV-Nephrology and Hypertension, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. markus.pirklbauer@i-med.ac.at.ORCID http://orcid.org/0000-0002-1211-0253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalBenzhydryl CompoundsGlucosidesHumansHypoglycemic AgentsInflammationRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAnti-Inflammatory Agents, Non-SteroidalBenzhydryl CompoundsempagliflozinGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAnti-inflammatory potentialEmpagliflozinHuman proximal tubulusNephroprotectionSGLT2 inhibition

Identifiers

PMID33728540
PMCPMC7997819

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.